The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells

Chemico-Biological Interactions

Volumn 183, Issue 1, 2010, Pages 172-180

  Chang, Horng Rong ^a,b   Huang, Hui Pei ^a   Kao, Yu Lin ^b   Chen, Sung Lang ^b   Wu, Sheng Wen ^b   Hung, Tung Wei ^b   Lian, Jong Da ^b   Wang, Chau Jong ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Ras; RhoA; RhoA kinase inhibitor

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; DNA; F ACTIN; GELATIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHALLOIDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; WORTMANNIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE RAS; PROTEIN EXPRESSION; WOUND HEALING; ZYMOGRAPHY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; AGED, 80 AND OVER; AMIDES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETON; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RAS PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 71349084410     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.10.018     Document Type: Article

References (43)

1. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Kiemeney L., Kriegmair M., Montironi R., Murphy W.M., Sesterhenn I.A., Tachibana M., and Weider J. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 Suppl. 1 (6) (2005) 4-34
2. Stenzl A., Cowan N.C., De Santis M., Jakse G., Kuczyk M.A., Merseburger A.S., Ribal M.J., Sherif A., and Witjes J.A. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 55 (2009) 815-825
3. Pashos C.L., Botteman M.F., Laskin B.L., and Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 10 (2002) 311-322
4. Chen C.H., Chiou H.Y., Hsueh Y.M., Chen C.J., Yu H.J., and Pu Y.S. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J. Urol. 181 (2009) 547-552
5. J.L. Xue, F. Dalleska, A.M. Murray, A.J. Collins, Cancer Prevalence in Patients with End-Stage Renal Disease, United States Renal Data System (USRDS) Annual Data Report, 2005.
6. Chang C.H., Yang C.M., and Yang A.H. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 109 (2007) 1487-1492
7. Wu M.J., Lian J.D., Yang C.R., Cheng C.H., Chen C.H., Lee W.C., Shu K.H., and Tang M.J. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am. J. Kidney Dis. 43 (2004) 1091-1097
8. Kao Y.L., Ou Y.C., Yang C.R., Ho H.C., Su C.K., and Shu K.H. Transitional cell carcinoma in renal transplant recipients. World J. Surg. 27 (2003) 912-916
9. Hung Y.M., Chou K.J., Hung S.Y., Chung H.M., and Chang J.C. De novo malignancies after kidney transplantation. Urology 69 (2007) 1041-1044
10. Yang M.H., Chen K.K., Yen C.C., Wang W.S., Chang Y.H., Huang W.J., Fan F.S., Chiou T.J., Liu J.H., and Chen P.M. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 59 (2002) 681-687
11. Shinohara N., and Koyanagi T. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?. Urol. Res. 30 (2002) 273-281
12. del Peso L., Hernandez-Alcoceba R., Embade N., Carnero A., Esteve P., Paje C., and Lacal J.C. Rho proteins induce metastatic properties in vivo. Oncogene 15 (1997) 3047-3057
13. Kamai T., Tsujii T., Arai K., Takagi K., Asami H., Ito Y., and Oshima H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9 (2003) 2632-2641
14. Wulf E., Deboben A., Bautz F.A., Faulstich H., and Wieland T. Fluorescent phallotoxin, a tool for the visualization of cellular actin. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 4498-4502
15. Hsieh Y.S., Chu S.C., Yang S.F., Chen P.N., Liu Y.C., and Lu K.H. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 28 (2007) 977-987
16. Chu S.C., Chiou H.L., Chen P.N., Yang S.F., and Hsieh Y.S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinog. 40 (2004) 143-149
17. Fujita J., Yoshida O., Yuasa Y., Rhim J.S., Hatanaka M., and Aaronson S.A. Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature 309 (1984) 464-466
18. Macaluso M., Russo G., Cinti C., Bazan V., Gebbia N., and Russo A. Ras family genes: an interesting link between cell cycle and cancer. J. Cell Physiol. 192 (2002) 125-130
19. Overall C.M., and Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6 (2006) 227-239
20. Chapman H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9 (1997) 714-724
21. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 366 (2005) 1736-1743
22. Yoon S.O., Shin S., Lee H.J., Chun H.K., and Chung A.S. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol. Cancer Ther. 5 (2006) 2666-2675
23. Chung T.W., Lee Y.C., and Kim C.H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/Akt pathways: involvement of invasive potential. FASEB J 18 (2004) 1123-1125
24. Lee S.O., Jeong Y.J., Im H.G., Kim C.H., Chang Y.C., and Lee I.S. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem. Biophys. Res. Commun. 354 (2007) 165-171
25. Huang H.P., Shih Y.W., Chang Y.C., Hung C.N., and Wang C.J. Chemoinhibitory effect of mulberry anthocyanins on melanoma metastasis involved in the Ras/PI-3K pathway. J. Agric. Food Chem. 56 (2008) 9286-9293
26. Oxford G., and Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J. Urol. 170 (2003) 1987-1993
27. Lemy A., Wissing K.M., Rorive S., Zlotta A., Roumeguere T., Muniz Martinez M.C., Decaestecker C., Salmon I., Abramowicz D., Vanherweghem J.L., and Nortier J. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51 (2008) 471-477
28. Cosyns J.P., Jadoul M., Squifflet J.P., Wese F.X., and van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33 (1999) 1011-1017
29. Arlt V.M., Stiborova M., and Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002) 265-277
30. Pan J.S., Hong M.Z., and Ren J.L. Reactive oxygen species: a double-edged sword in oncogenesis. World J. Gastroenterol. 15 (2009) 1702-1707
31. Chang H.R., Lian J.D., Lo C.W., Chang Y.C., Yang M.Y., and Wang C.J. Induction of urothelial proliferation in rats by aristolochic acid through cell cycle progression via activation of cyclin D1/cdk4 and cyclin E/cdk2. Food Chem. Toxicol. 44 (2006) 28-35
32. Debelle F.D., Nortier J.L., De Prez E.G., Garbar C.H., Vienne A.R., Salmon I.J., Deschodt-Lanckman M.M., and Vanherweghem J.L. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J. Am. Soc. Nephrol. 13 (2002) 431-436
33. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., and Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (2000) 1686-1692
34. Lord G.M., Cook T., Arlt V.M., Schmeiser H.H., Williams G., and Pusey C.D. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358 (2001) 1515-1516
35. Czerniak B., Cohen G.L., Etkind P., Deitch D., Simmons H., Herz F., and Koss L.G. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum. Pathol. 23 (1992) 1199-1204
36. Kroft S.H., and Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab Invest. 71 (1994) 158-174
37. Wallerand H., Robert G., Bernhard J.C., Ravaud A., and Ferriere J.M. Targeted therapy for locally advanced and/or metastatic bladder cancer. Prog. Urol. 18 (2008) 407-417
38. Przybojewska B., Jagiello A., and Jalmuzna P. H-ras, K-ras, and N-ras gene activation in human bladder cancers. Cancer Genet. Cytogenet. 121 (2000) 73-77
39. Duran A., Linares J.F., Galvez A.S., Wikenheiser K., Flores J.M., Diaz-Meco M.T., and Moscat J. The signaling adaptor p62 is an important NF-κB mediator in tumorigenesis. Cancer Cell 13 (2008) 343-354
40. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., and Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
41. Ishizaki T.T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., and Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol. Pharmacol. 57 (2000) 976-983
42. Imamura F., Mukai M., Ayaki M., and Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn. J. Cancer Res. 91 (2000) 811-816
43. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., and Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 5 (1999) 221-225